PL2925757T3 - Związki i kompozycje do leczenia chorób pasożytniczych - Google Patents
Związki i kompozycje do leczenia chorób pasożytniczychInfo
- Publication number
- PL2925757T3 PL2925757T3 PL13795977T PL13795977T PL2925757T3 PL 2925757 T3 PL2925757 T3 PL 2925757T3 PL 13795977 T PL13795977 T PL 13795977T PL 13795977 T PL13795977 T PL 13795977T PL 2925757 T3 PL2925757 T3 PL 2925757T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- compounds
- treatment
- parasitic diseases
- parasitic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728018P | 2012-11-19 | 2012-11-19 | |
| US201361847860P | 2013-07-18 | 2013-07-18 | |
| EP13795977.1A EP2925757B1 (en) | 2012-11-19 | 2013-11-18 | Compounds and compositions for the treatment of parasitic diseases |
| PCT/US2013/070601 WO2014078802A1 (en) | 2012-11-19 | 2013-11-18 | Compounds and compositions for the treatment of parasitic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2925757T3 true PL2925757T3 (pl) | 2018-06-29 |
Family
ID=49667630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13795977T PL2925757T3 (pl) | 2012-11-19 | 2013-11-18 | Związki i kompozycje do leczenia chorób pasożytniczych |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9556169B2 (pl) |
| EP (1) | EP2925757B1 (pl) |
| JP (1) | JP6298472B2 (pl) |
| CN (1) | CN105164124B (pl) |
| AR (1) | AR093532A1 (pl) |
| CY (1) | CY1119727T1 (pl) |
| DK (1) | DK2925757T3 (pl) |
| ES (1) | ES2655030T3 (pl) |
| HR (1) | HRP20171998T1 (pl) |
| HU (1) | HUE037600T2 (pl) |
| LT (1) | LT2925757T (pl) |
| ME (1) | ME03042B (pl) |
| PL (1) | PL2925757T3 (pl) |
| PT (1) | PT2925757T (pl) |
| RS (1) | RS56720B1 (pl) |
| SI (1) | SI2925757T1 (pl) |
| TW (1) | TWI600654B (pl) |
| UY (1) | UY35146A (pl) |
| WO (1) | WO2014078802A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| CA3012107A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Compounds and compositions for the treatment of cryptosporidiosis |
| TWI696615B (zh) * | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-***及雜芳基-***化合物 |
| JP7051804B2 (ja) * | 2016-07-14 | 2022-04-11 | エフ．ホフマン－ラ ロシュ アーゲー | 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物 |
| CN110023312A (zh) * | 2016-10-13 | 2019-07-16 | 由卫生与公众服务部部长代表的***合众国 | 阻止疟疾寄生虫传播的化合物和方法 |
| EP3609504A4 (en) | 2017-03-01 | 2021-03-03 | Anacor Pharmaceuticals, Inc. | NEW OXABOROLE ANALOGUES AND USES OF THE LATEST |
| CA3057087A1 (en) * | 2017-03-20 | 2018-09-27 | The Broad Institute, Inc. | Compounds and methods for the treatment of parasitic diseases |
| CN107037148B (zh) * | 2017-04-07 | 2019-11-19 | 上海药明康德新药开发有限公司 | 卤泛曲林的高效液相检测方法 |
| JOP20190278A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
| WO2020014068A1 (en) * | 2018-07-09 | 2020-01-16 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
| GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| CR20210477A (es) | 2019-03-19 | 2022-01-06 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos |
| JP2022535110A (ja) * | 2019-06-07 | 2022-08-04 | エランコ・ティアゲゾンタイト・アーゲー | 内部寄生虫を治療するための二環式誘導体 |
| CN116249704A (zh) | 2020-05-29 | 2023-06-09 | 勃林格殷格翰动物保健美国公司 | 驱虫用杂环化合物 |
| WO2023275590A1 (en) | 2021-06-29 | 2023-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations |
| WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3181279A1 (en) * | 2022-03-24 | 2023-09-24 | Bloom Energy Corporation | Fuel cell stack assembly including heat sink inserts |
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5348396A (en) | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
| EP0915880B1 (en) | 1996-07-24 | 2007-10-10 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| RU2199532C2 (ru) | 1997-06-27 | 2003-02-27 | Фудзисава Фармасьютикал Ко., Лтд. | Сульфонамидное соединение |
| JP2001139575A (ja) | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
| GB0002336D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| GB0002312D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| AU3740101A (en) * | 2000-03-01 | 2001-09-12 | Janssen Pharmaceutica Nv | 2,4-disubstituted thiazolyl derivatives |
| AU2001259242A1 (en) | 2000-04-28 | 2001-11-12 | Glaxo Group Limited | Process for the preparation of chemical compounds |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| AUPR916301A0 (en) | 2001-11-29 | 2001-12-20 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| BR0309475A (pt) | 2002-04-23 | 2005-03-01 | Shionogi & Co | Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004026871A1 (en) | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US7488745B2 (en) * | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| JP4943327B2 (ja) | 2004-07-16 | 2012-05-30 | シェーリング コーポレイション | 炎症性障害の処置のためのヒダントイン誘導体 |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| JP2008508358A (ja) | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
| JP2008516962A (ja) | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
| US8030327B2 (en) | 2004-11-08 | 2011-10-04 | Mds K.K. | Fused imidazole derivative |
| ATE430747T1 (de) * | 2004-12-21 | 2009-05-15 | Smithkline Beecham Corp | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren |
| WO2006070943A1 (ja) | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| US7713975B1 (en) | 2005-01-12 | 2010-05-11 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| CA2620223A1 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
| EP1963320A1 (en) | 2005-12-07 | 2008-09-03 | OSI Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| KR20080074161A (ko) | 2005-12-08 | 2008-08-12 | 노파르티스 아게 | ＥＰＨＢ 및 ＶＥＧＦＲ２ 키나아제 억제제로서의피라졸로[１,５-ａ]피리딘-３-카르복실산 |
| WO2007086080A2 (en) | 2006-01-30 | 2007-08-02 | Glenmark Pharmaceuticals Limited | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO2007100775A2 (en) | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| CA2654498A1 (en) | 2006-06-06 | 2007-12-21 | Avigen, Inc. | Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| JP2010503383A (ja) | 2006-09-12 | 2010-02-04 | ザ ジェネラル ホスピタル コーポレイション | 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法 |
| CN101516885A (zh) | 2006-09-29 | 2009-08-26 | 诺瓦提斯公司 | 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物 |
| WO2008052734A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| RU2487875C2 (ru) | 2006-11-06 | 2013-07-20 | Толеро Фармасьютикалз,Инк. | ПРОИЗВОДНЫЕ ИМИДАЗО [1,2-b]ПИРИДАЗИНА И ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗ |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| EP2124954A2 (en) | 2007-01-26 | 2009-12-02 | Irm Llc | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases |
| EP2167058B1 (en) | 2007-06-18 | 2015-08-12 | University Of Louisville Research Foundation, Inc. | Family of pfkfb3 inhibitors with anti-neoplastic activities |
| AU2008273050A1 (en) | 2007-07-11 | 2009-01-15 | Auckland Uniservices Limited | Pyrazolo[1,5-a]pyridines and their use in cancer therapy |
| ES2551095T3 (es) | 2007-07-19 | 2015-11-16 | Lundbeck, H., A/S | Amidas heterocíclicas de 5 miembros y compuestos relacionados |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2717034A1 (en) | 2008-02-28 | 2009-09-03 | Pascal Furet | Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| CA2718403A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| MX2010012457A (es) | 2008-05-13 | 2010-12-07 | Irm Llc | Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa. |
| JP2009298710A (ja) | 2008-06-11 | 2009-12-24 | Daiichi Sankyo Co Ltd | イミダゾ［１，２−ｂ］ピリダジン誘導体含有医薬組成物 |
| PL2310492T3 (pl) | 2008-06-30 | 2015-12-31 | Janssen Biotech Inc | Różnocowanie pluripotencjalnych komórek macierzystych |
| JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| EP2320737B1 (en) | 2008-08-05 | 2013-07-17 | Merck Sharp & Dohme Corp. | Pyrazolo-[1,5-a]-pyridines as mark inhibitors |
| US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| ES2710701T3 (es) * | 2008-09-24 | 2019-04-26 | Basf Se | Compuestos de pirazol para el control de plagas de invertebrados |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| US20120010188A1 (en) | 2008-12-04 | 2012-01-12 | Promimagen Ltd. | Imidazopyridine Compounds |
| WO2010074586A1 (en) | 2008-12-23 | 2010-07-01 | Pathway Therapeutics Limited | Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| JP2012521354A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| EP2408753A4 (en) | 2009-03-20 | 2012-11-07 | Univ Brandeis | COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS |
| US8927545B2 (en) | 2009-03-30 | 2015-01-06 | Duke University | Inhibiting Eph B-3 kinase |
| EP2417138B1 (en) | 2009-04-09 | 2019-11-27 | Merck Sharp & Dohme Corp. | Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors |
| UY32776A (es) * | 2009-07-09 | 2011-02-28 | Irm Llc | Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación. |
| RU2421455C2 (ru) | 2009-07-14 | 2011-06-20 | Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" | СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| TW201113286A (en) | 2009-09-03 | 2011-04-16 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| US20120214840A1 (en) | 2009-09-23 | 2012-08-23 | Panmira Pharmaceuticals, Llc | Indolizine inhibitors of 5-lipoxygenase |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| WO2014078813A1 (en) | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
-
2013
- 2013-11-18 WO PCT/US2013/070601 patent/WO2014078802A1/en active Application Filing
- 2013-11-18 LT LTEP13795977.1T patent/LT2925757T/lt unknown
- 2013-11-18 EP EP13795977.1A patent/EP2925757B1/en active Active
- 2013-11-18 ES ES13795977.1T patent/ES2655030T3/es active Active
- 2013-11-18 PT PT137959771T patent/PT2925757T/pt unknown
- 2013-11-18 US US14/443,609 patent/US9556169B2/en active Active
- 2013-11-18 DK DK13795977.1T patent/DK2925757T3/en active
- 2013-11-18 TW TW102141950A patent/TWI600654B/zh not_active IP Right Cessation
- 2013-11-18 SI SI201330889T patent/SI2925757T1/en unknown
- 2013-11-18 PL PL13795977T patent/PL2925757T3/pl unknown
- 2013-11-18 JP JP2015542882A patent/JP6298472B2/ja not_active Expired - Fee Related
- 2013-11-18 RS RS20171296A patent/RS56720B1/sr unknown
- 2013-11-18 ME MEP-2017-266A patent/ME03042B/me unknown
- 2013-11-18 HU HUE13795977A patent/HUE037600T2/hu unknown
- 2013-11-18 CN CN201380070822.0A patent/CN105164124B/zh not_active Expired - Fee Related
- 2013-11-19 UY UY0001035146A patent/UY35146A/es unknown
- 2013-11-19 AR ARP130104250A patent/AR093532A1/es unknown
-
2016
- 2016-07-26 US US15/220,149 patent/US9926314B2/en not_active Expired - Fee Related
-
2017
- 2017-12-27 HR HRP20171998TT patent/HRP20171998T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100008T patent/CY1119727T1/el unknown
- 2018-02-06 US US15/889,578 patent/US20180230145A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI2925757T1 (en) | 2018-01-31 |
| AR093532A1 (es) | 2015-06-10 |
| HUE037600T2 (hu) | 2018-09-28 |
| TWI600654B (zh) | 2017-10-01 |
| US20180230145A1 (en) | 2018-08-16 |
| PT2925757T (pt) | 2018-01-09 |
| US20160333012A1 (en) | 2016-11-17 |
| JP2016505529A (ja) | 2016-02-25 |
| US20150344471A1 (en) | 2015-12-03 |
| WO2014078802A1 (en) | 2014-05-22 |
| CN105164124B (zh) | 2017-03-15 |
| CN105164124A (zh) | 2015-12-16 |
| EP2925757A1 (en) | 2015-10-07 |
| US9926314B2 (en) | 2018-03-27 |
| RS56720B1 (sr) | 2018-03-30 |
| UY35146A (es) | 2014-06-30 |
| DK2925757T3 (en) | 2018-01-15 |
| EP2925757B1 (en) | 2017-10-04 |
| ME03042B (me) | 2018-10-20 |
| ES2655030T3 (es) | 2018-02-16 |
| TW201429967A (zh) | 2014-08-01 |
| JP6298472B2 (ja) | 2018-03-20 |
| HRP20171998T1 (hr) | 2018-02-09 |
| CY1119727T1 (el) | 2018-06-27 |
| LT2925757T (lt) | 2017-12-27 |
| US9556169B2 (en) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2925757T (pt) | Compostos e composições para o tratamento de doenças parasitárias | |
| IL241264A0 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| HK1212632A1 (zh) | 用於治療 介導的疾病的藥物組合物 | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| HK1213798A1 (zh) | 治療性化合物和組合物 | |
| EP2872151A4 (en) | ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | |
| EP2827856A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| EP2773342A4 (en) | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | |
| HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HK1205502A1 (en) | Compounds for the treatment of mtor pathway related diseases mtor | |
| HK1215794A1 (zh) | 用於治療疾病的同種異體自噬體富集組合物 | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| IL238592B (en) | Compounds for the treatment of liver diseases | |
| SG11201404649UA (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| SI2812351T1 (sl) | Farmacevtski sestavek za zdravljenje multiple skleroze | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |